SMS Lifesciences Stock Gained More Than 14% Today After API Facility Passes USFDA Inspection
By Ankur Chandra | Published at: Jul 16, 2025 04:36 PM IST
Hyderabad, July 16, 2025: SMS Lifesciences India Ltd (NSE: SMSLIFE, BSE: 540679) stock closed the day today, 16th July, up by 14.19% at Rs 1310.
This significant rally came after the company announced that it had received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API) manufacturing Unit 1 located in Kazipally, Telangana.
The inspection concluded with a “Voluntary Action Indicated” (VAI) status. This classification is a positive outcome for pharmaceutical manufacturers, indicating that while the USFDA investigators observed some objectionable conditions during the inspection, these issues are not severe enough to warrant regulatory or enforcement action at this time.
Stock Performance Snapshot (as of 3:15 PM IST, July 16, 2025)
| Metric | Value |
|---|---|
| Last Traded Price | ₹1,304.00 |
| Change (₹ / %) | ₹156.80 / +13.67% |
| Previous Close | ₹1,147.20 |
| Day’s High / Low | ₹1,376.60 / ₹1,164.30 |
| VWAP | ₹1,343.74 |
| Traded Volume (Lakh) | 0.83 |
| Traded Value (₹ Cr) | 11.21 |
| Buy Quantity | 11,197 shares |
| Sell Quantity | 3,873 shares |
Market Capitalisation and Valuation
| Parameter | Value |
|---|---|
| Total Market Cap | ₹403.49 Cr |
| Free Float Market Cap | ₹115.33 Cr |
| Adjusted P/E | 18.52 |
| Face Value | ₹10 |
| Annualised Volatility | 65.15% |
| 52-Week High (9-Sep-2024) | ₹1,749.65 |
| 52-Week Low (22-Jul-2024) | ₹815.00 |
Management Statement
In its regulatory filing dated July 16, the company stated:
“The receipt of EIR reaffirms the Company’s commitment to maintaining global quality standards and enables access to the regulated US market and other highly regulated global markets.”
This VAI classification is a significant milestone as it means the facility is deemed acceptable for continued operations and its products can continue to be supplied to the U.S. market. For an API manufacturer, USFDA approval is crucial because Active Pharmaceutical Ingredients (APIs) are the core components in any medicine, responsible for its therapeutic effect. The quality, safety, and efficacy of APIs directly impact the final drug product, making stringent regulatory oversight by bodies like the USFDA essential for global market access and patient safety.
Next Steps
With the USFDA issuing a VAI status for its Telangana API unit, SMS Lifesciences can continue exporting to the US – a critical market for its growth. The company is expected to address the minor inspection observations voluntarily, further strengthening compliance credibility. This regulatory green light opens the door for potential new product filings and expanded partnerships in regulated markets. Investors may watch for updates on US-bound API supplies, new approvals, or client additions. Sustained momentum in exports and consistent quality compliance could support long-term revenue and margin growth for the company.
About SMS Lifesciences
SMS Lifesciences India Ltd, listed on both NSE and BSE since August 2017, operates in the pharmaceutical sector with a focus on manufacturing Active Pharmaceutical Ingredients (APIs). The company’s regulatory-compliant manufacturing facilities serve key global markets, including the US, Europe, and other regulated jurisdictions.
REF: https://nsearchives.nseindia.com/corporate/SMSLIFE_16072025120624_Intimation.pdf
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
